still cold here in Perth, so thinking clearly
it seems important to point out: we are no longer a $1.5Bn prospective AML treatment.
we are a prospective $100Bn CPACS first in class, best in class, only one in class drug, with a $100Bn kicker for FTO first in class, best in class.
separately we could be $10Bn plus for the results in Melanoma alone
it's all there for anyone who wants to remove their blinkers and look at the results of work done to
date - RC220 provides the key to the door
Speculative M&A Transaction Analysis, page-852
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.46 | $143.9K | 96.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 230 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 550 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |